deucravacitinib
bms
['deucra']
#abst2132 #acr22 safety of deucravacitinib ph2psa&amp;ph3pso trial: no from bl in hematology, chemistry, or lipid labs. jak 1/2/3 effects on hem, hepatic, cpk, and cholesterol lab parameters not observed over 16 wks of deuc at doses up to 12 mg qd &amp; in combo w/csdmards. 
Rheumatologist at Scarsdale Medical Group, Runner, Traveler Opinions are my own